NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA-FETOPROTEIN

Abstract: The present invention is related to a non-human genetically modified mammal comprising a mutation, a partial or total deletion of the genetic sequence encoding the wild type mammal alpha-fetoprotein (AFP).

Description: NON-HUMAN GENETICALLY MODIFIED MAMMAL LACKING THE ALPHA-FETOPROTEIN Field of the invention [0001] The present invention is related to a non-human genetically modified mammal, preferably a knock-out mouse, comprising a partial or total deletion of a genetic sequence encoding the alpha- fetoprotein (AFP) and used as a model for the study of fertilization or contraceptive methods and drugs . [0002] The present invention is related to a non- human mammalian pluripotential embryonic stem cell comprising a partial or total deletion of a genetic sequence encoding a mammal alpha-fetoprotein (AFP) . [0003] The present invention is also related to study, testing and/or screening method and device of known or unknown compounds able to bind the mammal alpha- fetoprotein (AFP) and that may be used as agonist or antagonist of oestrogens to the mammal alpha-fetoprotein. Background of the invention [0004] Alpha-fetoprotein (AFP) is a glycoprotein present in the serum and a classical oncofetal marker. This protein is expressed at high levels during fetal life in the liver and the visceral endoderm of the yolk sac, and at lower levels in the developing gastrointestinal tract (Andrews et al . , 1982; Tilghman and Belayew 1982), in the adult serum only trace amount are detected (Tilghman and Belayew 1982) . The protein expressed by the embryos is secreted and present m the maternal blood circulation during gestation, the level of AFP concentration m the maternal serum is use to detect fetuses with spma bifida or Down's syndrome. The reason for this altered AFP level associated with those pathologies are not understood, but they have been used extensively m prenatal screening. The synthesis of AFP decreases dramatically after birth and only trace amounts are detected m adult liver. However expression of afp is associated with hepatocarcmomas and liver regeneration induced by partial hepatectomy or acute tetrachloπde (CC14) intoxication. The control of afp gene expression has thus attracted much attention and it has been shown that afp expression is regulated by transcriptlonal mechanisms involving a large promoter and three distant enhancers (review of Chen et al . (1997)) . Because AFP is synthesized during the Gl and S phases, it has been hypothesized that mtracellular AFP affects cell growth (Leffert and Sell, 1974; Sell et al . , 1975; Tsukada and Hirai, 1975; Belanger et al . , 1978) . The observation that AFP is able to bind estrogen led to the suggestion that AFP plays a role m the control of cell metabolism. In addition to binding estrogen, AFP, like albumin to which it is evolutionary related, is able to bind other steroids and endogenous and exogenous substances such as fatty acids, billirubm and various pharmaceutical agents suggesting that AFP may play a general transportation function. For the fetus, m this respect, AFP could serve as a modulator/modifier of various cell growth regulatory pathways during embryonic and fetal development m vertebrates by interacting and/or binding cytoplasmic chaperone proteins that normally escort nuclear receptors or transcription co- factors through the cytoplasm towards organelle interfaces (Mizejewski , 1995, 1985). AFP has also been proposed to protect the embryo against the maternal immune system, on the basis of the observation that addition of purified AFP into the culture of splenic or lymphnode mononuclear cells exerts a suppressive effect on antibody synthesis. [0005] The different hypotheses proposed for AFP function (s) can be focused on the fetal life (stage at which the gene is strongly transcripted) since the protein is described as a fetoprotein. [0006] At the present time, no document of the state of the art has suggested that the alpha- fetoprotein may play an essential role for female reproduction and fertility. Aims of the invention [0007] The present invention aims to provide new models (animal models) as well as new methods and devices for the study, the testing and/or the screening of fertilization or contraceptive methods, compounds and compositions intended for adult mammals (including humans) and/or for the study, the testing and/or the screening of new methods, compounds or compositions intended for the treatment and/or the prevention of osteoporosis. Summary of the invention [0008] The present invention is related to a non-human genetically modified mammal (preferably a knock-out mouse) comprising a mutation, a partial or total deletion m a genetic sequence encoding a mammal alpha-fetoprotem (AFP) described m GenBank (v00743). [0009] Advantageously, said mammal comprises an heterozygous or homozygous mutation, partial or total deletion m the genetic sequence encoding a mammal AFP. [0010] According to another embodiment of the present invention, said mammal is a sterile female comprising said homozygous mutation, partial or total deletion. [0011] The present invention is also related to specific sequences such as primers that are used to identify if a mammal comprises said mutation, partial or total deletion heterozygously or homozygousl . [0012] Another aspect of the present invention is related to a non-human mammal pluripotential embryonic stem cell, preferably a mouse pluripotential embryonic stem cell comprising a partial or total deletion of a genetic sequence encoding a mammal AFP. Said stem cell can be advantageously used to obtain the non-human genetically modified mammal according to the invention by methods well known by the person skilled m the art described hereafter. [0013] A further aspect of the present invention is related to the use of the non-human mammal according to the invention for the study, the testing and/or the screening of known or unknown anti -osteoporosis fertilization and/or contraceptive methods, compounds or compositions. [0014] A last aspect of the present invention is related to study, testing and/or screening methods and devices comprising the AFP or a portion of said AFP, preferably the AFP domain III comprising about 200 ammo acids (as described by Fest (1999) ) , being fixed upon a solid support and used as a substrate for known or unknown compounds or compositions m a competitive test or method. Said device comprises also a medium comprising (possibly labeled) oestrogens. The device according to the invention can be a chromatographic column upon which the AFP or the portion thereof is fixed or a study, testing and/or screening kit comprising disposed separately the various media necessary for said study, testing and/or screening. [0015] According to a preferred embodiment of the present invention, said device or kit may comprise a cell having integrated an oestrogen-sensitive (proloactme) promoter gene whose activation may result from the fixation of known or unknown compounds or compositions upon the AFP. Said known or unknown compound or composition could be used advantageously as an agonist of an oestrogen. [0016] The present invention is also related to this unknown agonist or antagonist of oestrogens screened and identified by the method and the device according to the invention. This unknown molecule finds an application the field of fertilization and/or contraceptive methods and compositions and/or is used also for the treatment and/or the prevention of osteoporosis. Detailed description of the present invention Generation of mice carrying a germ- line mutation m the AFP gene [0017] A clone containing a 129 genomic fragment of AFP loci was isolated from a lambda library. The library was screened with a probe containing the mouse afp promoter. The genomic insert of about 16 kb was subcloned pKIL-PCR2 (Gabant et al . , 1997). The targeting vector (pAFP K.O-1), consist of two recombination arms. The 5' arms (2.5 kb) was generated by polymerase chain reaction (PCR) using the following primers: N-Merl : agagcggccgcggaagtgacaaagcagaacc annealing to the Merl sequence of the afp enhancer 1 (Godboute et al . (1988)) and a primer of the X-exonl: agactcgagggatgagggaagcgggtgtg complementary to the afp exonl. The PCR fragment generated using Pfu polymerase (Stratagene) was cloned m the pCR- blunt vector (Invitrogen) . [0018] The 3' arms were subcloned from the lambda into pBSIIKS+ vector (Stratagene). The 5' recombination arm was introduced upstream the 3' recombination arm. The IRES lacZ/neo reporter-selective cassette was introduced between these recombination arms. The tk2 negative selective marker was introduced into the Sail site to generate pAFP KO-1. This construction was linearized with Notl and electroporated nto E14 ES cells. Correctly targeted clones were identified by Southern blot analysis using an external probe from the 5' region. ES cell injections and animal genotypmg [0019] Recombmant ES cells carrying the targeted allele were injected C57BL/6J blastocysts. Animals were genotyped by extraction of DNA from tails. RNA isolation, Northern blot analysis [0020] Total RNA was isolated using Tπzol (Gibco BRL) extraction according to the manufacturer instructions. For the Northern analysis 20μg of total RNA were electrophoresed and transferred to nylon membranes as described. Filters were then hybridized. Western blot analysis [0021] Proteins were separated by SDS-PAGE using 7.5% polyacrylamide gels a Bio-Rad Mini Protean gel chamber and blotted onto Nitrocellulose filters m a Bio- Rad Trans Blot chamber according to the manufacturer's instructions. Proteins were detected using anti-AFP, anti- Albumm; anti Betagalactosidase serum (ICN Biochemicals) the signal was detected with ECL detection system (Amersham) . LacZ reporter gene expression [0022] To isolate embryonic stages, natural matmgs were set up and presence of a vaginal plug at noon the following day was taken as 0.5 days of gestation. Staged embryos were stained with X-Gal as wholemounts as described by Forrester et al . (1996). For cryostat sectioning, tissues were embedded optimal cutting temperature (OTC) compounds (Miles, Inc., Elkart, IN), and sections stained for X-Gal were counterstamed with haematoxylm and eos , and mounted. Targeted mutagenesis of the afp gene [0023] The afp gene was disrupted by gene targeting embryonic stem (ES) cells. The lacZ reporter was introduced m afp gene by homologous recombination and placed under the control of the AFP promoter-enhancer region. The resulting allele is deleted for most of the sequence of exonl, for exon2 and 3 (see figure 1A) and homologous insertion was detected by Southern analysis (see figure IB) . To test the functionality of the reporter one may take advantage of the observation that AFP is expressed m embryoid bodies (Abe et al . , 1996) . Reporter gene activity is highly turn on some cells of these bodies (see figure 2A) . No expression of the reporter was detected undifferentiated ES cells grown the presence of LIF. [0024] ES cells afp lacZl/+ wer e injected into C57BL/6J blastocysts. Chimeπc animals were obtained and mated with outbred CD1 or inbred 129/CGR to test for germ line transmission. Phenotypically normal heterozygous mice afp lacZl/+ were generated and detected by Southern blot (see figure 1C) . Reporter expression analysis [0025] Expression of the lacZ reporter gene expression m embryonic and adult tissues was analyzed. As shown m Figure 2 the β-galactosidase activity was detected m predicted embryonic tissues. In the visceral endoderm only patches of cells were observed to turn the reporter strongly on. In the adult tissues tested specific staining was only detected cells of the liver and m cells of the gut . Animals without AFP are viable [0026] Intercrosses of heterozygotes { afp lacZl/+ ) gave rise to viable, apparently normal homozygous mutant mice at a Mendelian ratio m CD1 and C57/B16. On the other hand, a significant divergence was observed the 129 background (Table 1) . To determine whether the targeted allele indeed results a null mutation, total RNA from the liver of embryos was analyzed by Northern blot hybridization (Figure 3A) . A strong signal at 2.2kb corresponding to the afp transcript was detected wild type and heterozygous embryos. No signal was detected RNA samples extracted from homozygous embryonic liver, showing that the recombination disrupted the afp transcript m these animals. A Western blot was also performed on embryonic liver and amniotic fluid protein extracts (Figure 3B) and a strong signal was detected with the wild type extracts while no band corresponding to AFP was visible the homozygous extracts demonstrating that these animals do not express AFP. Table 1: Intercrosses AFP is required for female fertility [0027] The Mendelian ratio obtained CD1 and C57/black-6 background demonstrates that there is no reduction the intercrosses. On the other hand, the divergence observed 129 background suggests that AFP is involved m the gestation and that its importance is only revealed m some genetic contexts. In these litters derived from intercrossing heterozygous animals, homozygous embryos develop m the presence of their wild type and heterozygote littermates. AFP produced by these embryos is secreted and present the maternal serum. To determine whether afp lacZl/lacZl mi e are able to develop the complete absence of AFP, afp lacZl/lacZl ma les and afp lacZl/lacZl females were mated. No pups were obtained from these intercrosses suggesting an essential role of AFP for development and/or fertility (see Table 2) . To test if fertility was affected, afp lacZl/lacZl ma ι es an d females were mated with wild type animals. Males homozygous for an afp disrupted allele appeared fertile and sired offspring but homozygous females never produce any live offspring. To test if natural matmgs occur with the afp lacZl/lacZl females leave with wild type males the vaginal plug were checked. No plugs were detected with those females, showing that the origin of the observed infertility is due to an absence of mating. To identify the defect underlying the reproductive capacity of homozygous females, the reproductive system of those animals was analyzed. The reproductive system of the afp lacZl/lacZ l females was dissected and at this stage of the analysis appeared complete. A major anatomical difference is notable between ovaries from afp lacZl/lacZl anc a fp +/ + . j-^g ovaries of afp lacZl/lacZl are smooth, this observation suggests that those females do not ovulate. Histological analysis of mature afp lacZl/lacZl ovaries shown that their homozygous tissues do not contain corpus lutea, the lack of these structure is indicative of the absence of ovulation (see Figure 4) . The afp lacZ l /lacZ l ovaries contain follicles at the different stages of maturation, this suggests that the default of AFP during the development has no effect on the female gametogenesis . However, the presence of follicles does not prove that these gametes are competent for maturation. To test the competence of the afp lacZl/lacZl follicles, they were dissected out and analyzed their potential of maturation in vi tro . Complete maturation was obtained m vi tro with the dissected oocytes from afp lacZl/lacZl animals. Taken together these data indicates that those females do not ovulate properly and thus that a signal needed to trigger ovulation is absent m the afp lacZl/lacZl m ιce . Table 2 : Phenotypical analysis Table 2- Infertility phenotype of the af lacZ1 / lacZ1 (-/-) homozygous animals were mated, no offsprings were obtained from these matmgs. To test fertility of the a fp^ & cZ±/ lacZl { - / - ) males and females, homozygous males and females were mated with wild type ( +/+ ) animals. For the different breedings the number of mating is given brackets. [0028] It was also observed that a fp lacZ1 / lacZ1 follicles are able to mature normally in vi tro (data not shown) suggesting that the defect could be a signal required to trigger ovulation and indeed ovulation can be induced these animals by a superovulation protocol (Table 3) . Table 3 ; Ovulation induction in af " p-*- acZ ^-/ + and afp lacZl/lacZl females Table 3 : Induction of ovulation a fp±acZl/ ~ La.cZl females. a fplacZl/lacZl an( j L a fplacZl/ + females were hormonally treated to induce ovulation. The average number of postovulation oocytes obtained from 6 individual females tested. Mouse genotyp g by PCR [0029] In order to identify a possible mutation or deletion the afp gene, a specific genotypmg of afp -/- mice by PCR has been developed. Two primers are used for the first afp#l anneals m the afp promoter region (-116 bp to -137 bp) : according to the +1 of the mouse afp gene) . The second primer afp#2 is complementary to the first exon of the mouse afp gene (+141 bp to +160 bp : according to the +1 of the mouse afp gene) : sequence deleted the afp - / - knock-out mouse described the text . Sequence afp#l : cccctgctctgtt v aattattg Sequence afp#2 : gaaaatagctcccaagtcac [0030] No amplification product (300 bp) was observed afp -/- animals. This amplification is present in wild type and heterozygous mice. [0031] To differentiate +/- from wild type, a second PCR is performed using two primers giving an amplification on the DNA introduced the genome of the transgemc animals (this sequence is not present m wild type animals) . [0032] For the knock-out mouse for afp described the text : a couple of primers complementary to lacZ (E. coll gene) can be used. lacZ#l : acaacgtcgtgactgggaaaac lacZ#2 : taatgggataggttacgt [0033] Those primers will only give a signal (287 bp) on +/- and no signal on wild type DNA samples. [0034] The physiological role of the alpha- fetoprotem, the most abundant serum protein expressed by mammalian embryos remains to be establish . This protein related to albumin excreted by the embryos into the maternal blood circulation has attracted attention and due to its abundance it has been postulated that the presence of this protein was essential for embryonic development. To determine the function of AFP this gene was disrupted by homologous recombination m embryonic stem cells. Surprisingly homozygous a fpi-S-cZl/la Zl are viable showing that expression of AFP by the embryo itself is not require for normal and complete development. This phenotype shows that the structure of the homozygous females was generally maintained. The different stages of ovocytes maturation are founded these ovaries and shown to accomplish their maturation in vi tro . Ovulation was induced m these females by hormonal induction and ovocytes were produced. Although AFP is synthesized at a high level during fetal life (mainly by the liver and the visceral endoderm of the yolk sac) , low level of AFP mRNA has been reported different other fetal and adult tissues as well as m adult rats. However, the level of expression in such tissues is very low. Another explanation is that the ovulation those females is affected by the lack of AFP during development . [0035] The fact that adults a f p lacZl/lacZl ovulation can be induced argues for the absence those females of a signal needed to trigger ovulation. This suggests that AFP is involved the transportation of an element needed for ovulation the adults. [0036] By the disruption of the mouse AFP, one may show that fetal serum protein is required for females ovulation. [0037] The fact that analbummic rats are fertile shows that at least albumin cannot rescue AFP. This show that albumin and AFP plays two different role and that AFP is involved m the function of females ovaries. [0038] The specific phenotype of the non-human mammals according to the invention is also illustrated the enclosed figure 4, which presents the anatomical and histological analysis for the afpl acZ1 /l acZ1 ovaries: A: Structure of the ovary (arrow) and uterus of an adult afp lacZl/lacZl (_/_) female ; B: Ovary from 12 weeks old a fp lacZ1 / lacZ1 ; C: Ovary from a 12 weeks old wild type female: the surface distortions are due to the presence of large type follicles, whereas afpl cZ1 /l acZ1 ovarιes are smooth; D: The general histological structure of the afp-'- acZ::1 -/l ac 1 ovaries is not affected and mature Graafian follicles are present those tissues (section from a fourth month old female) ; E: At 4 months, the wild type ovaries exhibit large corpus lutea, indicative of successful ovulation. Those structures are never found af acZl/ lac l ovaries. [0039] Therefore, the non-human female mammals that present homozygously said mutation, partial or total deletion m the afp gene do not cycle. The surface of the ovaries is smooth and is not characterized by the presence of large follicles. Their histological structure is not generally affected, and Graafian follicles are identified the tissues but no large corpus lutea is present. [0040] Furthermore, females comprising an homozygous mutation or partial or total deletion m the afp gene do not allow uterus nidification of an embryo. [0041] Additional experiments have shown that the afp gene is not essential for the survival of the mice. Indeed, as females give birth to severa animals, it was possible that the afp ~ ' ~ may survive to brothers and sisters ( afp + ' + or afp + ' ~ ) simultaneously present m the uterus of the female. [0042] Therefore, in order to extrapolate the observed phenotype and genotype to the human population, the inventors have shown that blastocysts implanted one by one pseudogravite females will obtain the birth of alive afp ~ * animals that present the same phenotype as above- described (fertile males, sterile females) . [0043] Therefore, the afp ' i phenotype corresponds to alive sterile females, which is a phenotype that may exist the mouse population as well as m the human population. REFERENCES - Andrews G.K et al . , J. Biol . Chem. 257 pp. 5148-5153 (1982) - T lghman S.M and Belayew A., Proc . Natl . Acad. Sci . USA 79 pp. 5254-5257 (1982) - Godbout R. et al . , Mol . Cell. Biol . 6 pp. 477-487 (1986) - Godbout R. et al . , Mol. Cell. Biol. 8(3) pp. 1169-1178 (1998) - Chen H et al . , Critical Rev. In Eucaryotic Gene Expression 7 pp. 11-41 (1997) - Festm et al . , Biochem. & Biophys. Acta 24789 pp. 307- 314 (1999) - Leffert H. L. and Sell S., J. Cell Biol. 61 pp. 823-829 (1974) - Sell S. et al . , Ann. NY Acad. Sc . 259 pp. 45-58 (1975) - Tsukada Y. and Hirai H., Ann. NY Acad. Sci. 259 pp. 37- 44 (1975) - Belanger L. et al . , Scand. J. Immunol. 8 (Suppl 8) pp. 239-246 (1978) - Mize ewski G.J. New insights into AFP structure and function: potential biomedical applications. In Mizejewski G.J., Porter IH (eds) . Alpha-Fetoprotem and congenital disorder. Orlando :Academιc Press :5-34 (1985) - Mizejewski G.J., Life Sci. 56 pp. 1-9 (1995) - Abe K. et al . , Exp . Cell Res. 25 pp. 27-34 (1996)

Claims: CLAIMS 1. A non-human genetically modified mammal comprising a mutation, a partial or total deletion m the genetic sequence encoding the wild type mammal alpha-fetoprotem (AFP) . 2. The non-human mammal according to claim 1, characterized m that it is a mouse. 3. The non-human mammal according to claim 1 or 2, characterized that it comprises a heterozygous mutation, partial or total deletion the genetic sequence encoding the wild type mammal alpha-fetoprotem (AFP) . 4. The non-human mammal according to claim 1 or 2, characterized that it comprises an homozygous mutation, partial or total deletion m the genetic sequence encoding the a wild type alpha-fetoprotem (AFP) . 5. The non-human mammal according to claim 4, characterized m that it is a sterile female. 6. The non-human mammal according to claim 5; characterized m that it does not present a menstrual cyclization. 7. The non-human mammal according to claim 5, characterized m that it does not allow an uteral mdification of an embryo. 8. Use of the non-human mammal according to any one of the preceding claims, for the study, the testing and/or the screening of anti-osteoporosis fertilization and/or contraceptive methods, compounds and compositions. 9. A pluripotential embryonic stem cell, preferably a mouse cell, comprising a partial or total deletion of a genetic sequence encoding a mammal alpha- fetoprotem (AFP) . 10. A study, testing and/or screening method and device of known or unknown molecules that are able to fix the alpha-fetoprotem or a portion thereof and that may be used as agonists or antagonists of oestrogens, for fertilization and/or contraceptive methods and compositions and/or the prevention and/or the treatment of osteoporosis.

Inventors: GABANT PHILIPPE, ROSCAM-SZPIRER JOSIANE, GABANT, PHILIPPE, ROSCAM-SZPIRER, JOSIANE
Applicants: GABANT PHILIPPE, ROSCAM SZPIRER JOSIANE, UNIV BRUXELLES, GABANT, PHILIPPE, ROSCAM-SZPIRER, JOSIANE, UNIVERSITE LIBRE DE BRUXELLES
Application year: 2000
Main classification: A01K67
IPC codes: C12N15